There are currently 48 active clinical trials seeking participants for Prostate Adenocarcinoma research studies. The states with the highest number of trials for Prostate Adenocarcinoma participants are Illinois, California, Wisconsin and Pennsylvania.
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
Recruiting
Background: The current standard treatment of prostate cancer is either surgery or radiation. Typically, this includes either the removal or radiation of the whole prostate gland. Many people now seek out focal therapy options to decrease the side effects of treatment. Until now, several forms of physical destruction with heat (thermal ablation), cold (cryotherapy), sound waves (HIFU), laser (FLA), and electrical energy (IRE). A new type of radiation (SBRT) may be an effective way to cure men o... Read More
Gender:
MALE
Ages:
Between 18 years and 120 years
Trial Updated:
05/22/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Prostatic Neoplasms, Prostate Cancer, Prostate Adenocarcinoma
rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance
Recruiting
This clinical trial evaluates whether positron emission tomography-magnetic resonance imaging (PET-MRI) using the radioactive drug radiohybrid prostate-specific membrane antigen (rhPSMA)-7.3 may help in detecting higher grade or stage disease in men with low and favorable intermediate risk prostate cancer who are candidates for active surveillance. A PET scan is a test that uses a radioactive drug and a computer to create images of how organs and tissues in the body are functioning. The radioact... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8
The Use of Ultrasound in Assessing Post-prostatectomy Erectile Dysfunction
Recruiting
Researchers are trying to determine whether there is additional utility to using vibroelastography, a noninvasive ultrasound technique to evaluate for the presence of tissue fibrosis, in conjunction with standard penile duplex Doppler ultrasound to assess erectile function (recovery) after prostate cancer surgery.
Gender:
MALE
Ages:
40 years and above
Trial Updated:
05/19/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Prostate Adenocarcinoma
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
Recruiting
This phase II trial studies how well atezolizumab works alone or in combination with etrumadenant or tocilizumab in treating men with localized prostate cancer before radical prostatectomy. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Androgens can cause the growth of prostate cancer cells. IL-6 is expressed by prostate cancer and within the tumor microenv... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: University of California, San Francisco, San Francisco, California +1 locations
Conditions: Prostate Adenocarcinoma, Prostate Cancer, Localized Prostate Cancer
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Recruiting
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk prostate cancer. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period of time. This trial is evaluating if shorter duration radiation preve... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +290 locations
Conditions: Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Prostate Adenocarcinoma
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
Recruiting
This phase III trial uses the Decipher risk score to guide therapy selection. Decipher score is based on the activity of 22 genes in prostate tumor and may predict how likely it is for recurrent prostate cancer to spread (metastasize) to other parts of the body. Decipher score in this study is used for patient selection and the two variations of treatment to be studied: intensification for higher Decipher score or de-intensification for low Decipher score. Patients with higher Decipher risk scor... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +558 locations
Conditions: Prostate Adenocarcinoma
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
Recruiting
This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or reduce the growth of prostate cancer cell growth by blocking the attachment of androgen to its receptors on cancer cells, a mechani... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Cancer Center at Saint Joseph's, Phoenix, Arizona +334 locations
Conditions: Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
Recruiting
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiatio... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Fairbanks Memorial Hospital, Fairbanks, Alaska +590 locations
Conditions: Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial
Recruiting
This phase II randomized control trial assesses the effect of Urolithin A (Uro-A) supplementation compared to placebo in men with biopsy-confirmed prostate cancer undergoing radical prostatectomy (RP) progressive disease. A total of 90 men will be accrued and randomized 1:1 to receive a 1000 mg daily dose of Uro-A in two 250 mg capsules PO BID or two placebo capsules BID daily for 3 to 6 weeks prior to RP. The primary endpoint is to determine the effect of Uro-A on decreasing prostate tumor tiss... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/02/2025
Locations: Cedars Sinai Medical Center, Los Angeles, California +4 locations
Conditions: Prostate Adenocarcinoma
Two-fraction HDR Monotherapy for Localized Prostate Cancer
Recruiting
This is a single center single arm prospective pilot study investigating the safety of high dose rate (HDR) brachytherapy as monotherapy delivered in 2 fractions 3 hours apart. HDR monotherapy has been established as safe and effective in this context, however previous studies have delivered 2 fractions on separate days, or at least 6 hours apart. Clinically, this regimen, if shown to be safe and effective in future studies, has the potential to reduce operative resources and logistical stresses... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: University of California, San Francisco, San Francisco, California
Conditions: Prostate Adenocarcinoma, Localized Prostate Carcinoma
A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer
Recruiting
The purpose of this study is to find out the effects of exercise therapy on indicators of prostate cancer in people with low-risk prostate cancer who are on active surveillance. The exercise therapy in this study will be regular home-based walking sessions on a treadmill, and that therapy will be assigned by an exercise physiologist (a medical professional who studies how exercise affects the human body). Some participants in this study will have the assigned exercise therapy, and some participa... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: University of California, Los Angeles (Data and Specimen Analysis Only), Los Angeles, California +8 locations
Conditions: Prostate Cancer, Prostate Adenocarcinoma, Localized Prostate Carcinoma
An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer
Recruiting
This trial studies how well 68Ga-PSMA-11 PET scan works in imaging patients with prostate cancer. Diagnostic procedures, such as 68Ga-PSMA-11 PET may find and diagnose prostate cancer and improve monitoring of treatment response.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Biochemically Recurrent Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8